View this email in your browser

Special Edition: ACRO’s COVID-19 Response

The Global Clinical Research Industry’s Commitment to Collaboration during the COVID-19 Pandemic 

Given the emerging global public health crisis, ACRO and its members reaffirm our commitment to collaborating with regulators and biopharmaceutical organizations worldwide to develop vaccines and anti-viral therapies to prevent, diagnose, and treat COVID-19. The expertise and innovation of ACRO member companies helps speed the clinical trial process and the development of safe and effective therapies. ACRO’s clinical research and technology companies are supporting trials in real-time to address the outbreak.

On March 13, 2020, ACRO released a list of considerations that support clinical trial monitoring during COVID-19. ACRO suggests that sponsors, CROs, and sites introduce emergency interim measures so that clinical trial monitoring is maintained during this period.

The monitoring considerations posted on our website will help to ensure that data quality is unaffected, clinical trial sites are supported, and that the patients enrolled in clinical trials are kept safe. You can download the recommendations here.
ACRO will continue to share recommendations as the situation develops. If you have colleagues who want to stay updated on the latest regarding ACRO’s response to COVID-19, please forward this email and invite them to subscribe to our newsletter here. You can also follow @ACROhealth on Twitter. 

Get social with us!

Copyright © 2020 Association of Clinical Research Organizations, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp